Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

@article{LuEmerson2015LessonsFA,
  title={Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.},
  author={Christine Lu-Emerson and Dan G Duda and Kyrre Eeg Emblem and Jennie W. Taylor and Elizabeth R. Gerstner and Jay S. Loeffler and Tracy T Batchelor and Rakesh K. Jain},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 10},
  pages={
          1197-213
        }
}
Treatment of glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains a significant unmet need in oncology. Historically, cytotoxic treatments provided little durable benefit, and tumors recurred within several months. This has spurred a substantial research effort to establish more effective therapies for both newly diagnosed and recurrent GBM. In this context, antiangiogenic therapy emerged as a promising treatment strategy because GBMs are highly vascular tumors… CONTINUE READING
Highlighted Tweets
This paper has been referenced on Twitter 13 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 59 CITATIONS, ESTIMATED 49% COVERAGE

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

  • Averaged 11 Citations per year from 2017 through 2019